The oncology drug specialist has secured $100m from investors including existing shareholder Lilly Asia Ventures.

China-based oncology biotechnology developer Ionova Life Science has raised $100m in funding from investors including Lilly Asia Ventures, a corporate venture capital vehicle for pharmaceutical firm Eli Lilly.

Greater Bay Area Homeland Development Fund co-led the round together with Tsing Song Capital and Shenzhen Capital Group, while Dyee Capital also took part.

Founded in 2016, Ionova Life Sciences specialises in developing drugs to treat cancer, including immuno-oncology and targeted delivery.

The funding will be used to accelerate pipeline development, including…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn